APTO vs. SNTI, EVAX, PMCB, ZIVO, AIM, TVGN, BCLI, COEP, CRTX, and CHRO
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Senti Biosciences (SNTI), Evaxion Biotech A/S (EVAX), PharmaCyte Biotech (PMCB), ZIVO Bioscience (ZIVO), AIM ImmunoTech (AIM), Tevogen Bio (TVGN), Brainstorm Cell Therapeutics (BCLI), Coeptis Therapeutics (COEP), Cortexyme (CRTX), and Chromocell Therapeutics (CHRO). These companies are all part of the "medical" sector.
Aptose Biosciences (NASDAQ:APTO) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations.
Aptose Biosciences has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.88, indicating that its share price is 188% more volatile than the S&P 500.
Aptose Biosciences has a net margin of 0.00% compared to Senti Biosciences' net margin of -2,692.82%. Senti Biosciences' return on equity of -79.71% beat Aptose Biosciences' return on equity.
Aptose Biosciences has higher earnings, but lower revenue than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
Aptose Biosciences currently has a consensus target price of $19.80, indicating a potential upside of 1,577.82%. Senti Biosciences has a consensus target price of $6.00, indicating a potential upside of 1,478.95%. Given Aptose Biosciences' higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Senti Biosciences.
In the previous week, Senti Biosciences had 1 more articles in the media than Aptose Biosciences. MarketBeat recorded 9 mentions for Senti Biosciences and 8 mentions for Aptose Biosciences. Aptose Biosciences' average media sentiment score of 0.46 beat Senti Biosciences' score of -0.11 indicating that Aptose Biosciences is being referred to more favorably in the media.
26.6% of Aptose Biosciences shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 9.5% of Aptose Biosciences shares are held by insiders. Comparatively, 12.5% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Aptose Biosciences received 372 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 65.79% of users gave Aptose Biosciences an outperform vote while only 33.33% of users gave Senti Biosciences an outperform vote.
Summary
Aptose Biosciences beats Senti Biosciences on 9 of the 16 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
